C4 Therapeutics vs Voyager Therapeutics
CCCC and VYGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CCCC and VYGR compare
C4 Therapeutics is the larger company, worth 3.3 times as much as Voyager Therapeutics ($356M against $108M).
C4 Therapeutics grew revenue faster over the last twelve months (7.2% versus −19.8% for Voyager Therapeutics).
C4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −282% compared with −416% at Voyager Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CCCC | VYGR |
|---|---|---|
| Size and price | ||
| Market cap | $356M | $108M |
| Share price | $2.89 | $1.76 |
| Change, 1 year | 23.5% | −58.7% |
| Change, 5 years | −92.5% | −46.5% |
| Beta (5Y) | 2.52 | 1.20 |
| Employees | 104 | 141 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.0× | 4.3× (better) |
| P/B | 1.6× | 0.8× (better) |
| FCF yield | −22.4% (better) | −101% |
| Fair value | $2.43 | $2.98 |
| Margin of safety | −18.7% | 41.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.2% (better) | −19.8% |
| Revenue growth, 5Y average | – | −25.1% |
| Profitability | ||
| Operating margin | −316% (better) | −450% |
| Net margin | −282% (better) | −416% |
| FCF margin | −247% (better) | −437% |
| Return on equity | −47.6% (better) | −58.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.17 | 6.81 (better) |
| Altman Z-score | −1.65 (better) | −3.89 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 0.07% | – |
| Shareholder yield | 0.07% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.6% | 56.9% |
| Held by insiders | 2.8% | 2.6% |
| Insider net buying, 12 months | −$22.2K (better) | −$298K |
| Short interest, % of float | 38.9% | 7.3% |
Go deeper
- CCCC stock overview
- CCCC income statement
- CCCC valuation and score
- VYGR stock overview
- VYGR income statement
- VYGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.